不同劑型短效rhGH治療矮小癥患者的有效性、安全性及經(jīng)濟(jì)性評價(jià)
打開文本圖片集
中圖分類號 R969；R956;R977.1 文獻(xiàn)標(biāo)志碼A 文章編號 1001-0408（2025）09-1111-06
DOI 10.6039/j.issn.1001-0408.2025.09.16
ABSTRACTOBJECTVETocomparetheefcacy，safety，andcost-efectivenessof twodiferentformulationsofshort-acting recombinant human growth hormone（rhGH）in thetreatmentof patients with short stature.METHODSData frompatients with shortstaturetreatedwithshort-actingrhGHattheLeshanPeople’sHospitalfromAugust2O16toJune2023werecolectedPatients weredividedinto powder formulation groupandaqueous formulation groupbasedontherhGH formulationused.Thechanges in growth-relatedeficacyindicatorsandtheoccurrenceof adversedrugreactions werecomparedbetwentwo groupsafterl2months oftreatment；cost-effectivenessanalysisandsensitivityanalysiswereusedtocomparethecostperunitofefectacheved；subgroup analysis wasperformedbydividingthepatients intogrowthhormonedeficiency（GHD）subgroupandidiopathicshortstature（Is） subgroupbasedonclinical diagnosis.RESULTSAfter12 monthsoftreatment，theheightandthelevelsof insulin-likegrowth factor-landinsulin-likegrowthfactorbindingprotein-3inseruminaqueous formulation groupand powderformulationgroup were
significantly increased compared to before treatment（ P < 0.001），but there was no statistically significant difference in the changes of the above indicators between the two groups 1 （P>0 . 0 5 ）.Theanalysis results of GHD and ISS subgroups were consistent with the overall population. In the overall
population，the cost-effectiveness ratio of powder formulation group 2 5 8 2 y u a n / c m ）was significantly better than that of aqueous formulation group（6 729 yuan/cm），with a statistically significant difference（ P < 0 . 0 0 1 ），and the result was consistent in the GHD and ISSsubgroupsas wellasin thesensitivityanalysis.Noseriousadverse drug reactions ocurred in either powder formulationoraqueous formulationgroup，andtherewasnostatisticallysignificantdiferenceintheincidenceofvariousadverse reactions between two groups （ ΔP>0 . 0 5 ）.CONCLUSIONS Short-acting rhGH powder and aqueous formulations have equivalent efficacy and safety，but the powder formulation has greater economic advantages.
KEYWORDSrecombinant humangrowthhormone；formulation；eficacy；safety；cost-effectiveness；short stature；growth hormone deficiency；idiopathic short stature
我國矮小癥患者發(fā)病率約為 3 % ，全國約有4100萬例矮小癥患者，但得到正規(guī)治療的不足3萬例[1-2]。（剩余8575字）